GLQ223 alpha-trichosanthin data

GNLB (Redwood City, Calif.) completed analysis of its Phase II trial, saying that the use of steroids in the study had masked the primary end point of CD4 counts, and that further evaluation of the product is merited.

Steroids had been given in the study to control side effects expected from trichosanthin. Statistical analyses that took the known lymphocyte-lowering action of steroids into account showed an encouraging activity of the drug, the company said. ...